TD Cowen raises DexCom stock price target to $95 on data

TD Cowen raised its DexCom price target to $95 from $75 while keeping a Buy rating, citing the CONNECT and MACE data, T2NIT coverage expansion, and upside from the 15-day rollout, international Stelo launch, and Prime commercial coverage. The new target implies 6.1x TD Cowen’s 2027 sales estimate of $5.84 billion, and follows prior target increases from other brokers despite some margin concerns elsewhere. DexCom shares were already up 7.5% over the past week and 18% year-to-date on the improving catalyst backdrop.

Analysis

The market is starting to price DexCom less as a premium CGM pure-play and more as an access story with multiple shots on goal. The key second-order effect is that broader reimbursement for non-insulin type 2 patients expands the category faster than it redistributes share, which should lift the whole addressable market first and only later create a winner-take-most dynamic. That said, if DexCom is truly at the front of the coverage push, the operating leverage could be disproportionate because each incremental covered patient should have very high gross margin and limited incremental sales cost once payer friction drops.

The more interesting nuance is timing: the equity is likely discounting 2027-2028 acceleration well before it shows up in reported growth, so near-term upside depends on maintaining confidence through a period where guidance may still look conservative. That creates a classic setup where any evidence of faster commercial uptake, faster-than-expected international ramp, or better mix from newer products can extend multiple expansion, while a single margin miss could compress it quickly because the stock is no longer trading as a sleepy medtech compounder. The recent analyst upgrades suggest the sell-side is converging around a higher terminal growth narrative, which raises the risk that consensus becomes too comfortable on pricing power and reimbursement timing.

Competitively, the biggest loser is not necessarily a named rival, but any diabetes hardware vendor with less compelling payer evidence or weaker software/app ecosystem. If payers standardize coverage on measured outcomes, the battle shifts from device specs to data quality, adherence, and channel control, which favors the incumbent with the broadest clinical dossier and strongest clinician pull-through. The contrarian risk is that CMS adoption and commercial coverage can lag by quarters, not weeks, and if reimbursement rollout proves uneven, the market may be overpaying for a 2027 story with 2025-2026 execution risk still unresolved.

Key Decisions for Investors

• Stay long DXCM on pullbacks for a 3-6 month horizon; upside is extension of the reimbursement/multiple re-rating, but size modestly because the name already reflects part of the coverage optionality.
• Buy DXCM 6-12 month call spreads financed by selling farther OTM upside to express continued re-rating toward the new higher sell-side band without taking full delta exposure.
• Pair long DXCM vs short a weaker diabetes-device/CGM peer basket over 3-6 months to isolate reimbursement leadership from broader medtech beta; thesis is payer evidence and channel strength drive share gains.
• If holding a core long, hedge with near-dated puts around reimbursement or guidance events; the stock is vulnerable to a sharp de-rate if 2026 guidance remains conservative and the market starts questioning 2027 timing.
• Monitor journal publication and any CMS commentary as the next catalyst window; if those are delayed beyond the next 1-2 quarters, reduce exposure because the stock is likely to enter a time-decay phase.